EOI::implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI full termination
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93023C00012
- Awardee
-
Pluri Biotech LTD UEI MEDCUE4LMZE6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,861,615
Award facts
- Opportunity
-
- Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Bio-dosimetry Devices Pre-Solicitation · 75N93021R00019 · Posted Nov 15, 2021
- Contract value 69% obligated
-
- $2,861,615.00 Current, with exercised options
- $4,175,467.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 16 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Israel
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Exercise an Option | $1,416,470 | |
| Other Administrative Action | $0 | |
| Original award | $1,445,145 |
About this award
This $4,175,467 definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Pluri Biotech LTD, a for-profit limited liability company based in Israel, for the development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome.
The contract, which has no set-aside designation, supports research and development efforts focused on creating safe and effective medical countermeasures to mitigate radiation-associated mortality and morbidity, as well as advancing biodosimetry biomarkers and devices to inform triage and treatment strategies for mass casualty radiation incidents. Key requirements include demonstrating the lead medical countermeasure's efficacy when administered at least 24 hours post-exposure, and establishing target product profiles for both the medical countermeasure and biodosimetry approaches.
Quick answers
Who was awarded contract 75N93023C00012?
75N93023C00012 was awarded to Pluri Biotech LTD by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2023.
How much is contract 75N93023C00012 worth?
The government has obligated $2,861,615 on 75N93023C00012. Its potential value, with all options, is $4,175,467.
Was contract 75N93023C00012 competed?
The extent of competition for 75N93023C00012 was full and open competition. The government received 16 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award